NATCO announces launch of breast cancer medicine Lapatinib Tablets in the U.S.

Natco Pharma Limited {NSE: NATCOPHARM; BSE: 524816) has announced that its marketing partner, Lupin Limited (Lupin), has launched Lapatinib Tablets, 250 mg, in the United States market after NATCO received the final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Federal Drug Administration (USFDA). NATCO was the 1st ANDA applicant for Lapatinib Tablets, 250mg, containing a Paragraph IV certification.

Lapatinib Tablets, 250mg, is sold under Brand name TYKERB®, of Novartis Pharmaceuticals Corporation (Novartis), which is indicated primarily for the treatment of certain types of breast cancer. For the 12 months ending June, 2020, TYKERB® had sales of approximately USO 61 million in the U.S. (IQVIA MAT June 2020).

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.950.2 as compared to the previous close of Rs. 953.4. The total number of shares traded during the day was 49489 in over 3197 trades.

The stock hit an intraday high of Rs. 976.4 and intraday low of 935.3. The net turnover during the day was Rs. 47681211.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.950.2 as compared to the previous close of Rs. 953.4. The total number of shares traded during the day was 49489 in over 3197 trades.

The stock hit an intraday high of Rs. 976.4 and intraday low of 935.3. The net turnover during the day was Rs. 47681211.

Shares of LUPIN LTD. was last trading in BSE at Rs.1006.6 as compared to the previous close of Rs. 998. The total number of shares traded during the day was 124827 in over 4463 trades.

The stock hit an intraday high of Rs. 1025.35 and intraday low of 991. The net turnover during the day was Rs. 126138290.

Source : Equity Bulls

Keywords